Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) issued its earnings results on Thursday. The company reported ($2.25) EPS for the quarter, topping analysts’ consensus estimates of ($3.68) by $1.43, FiscalAI reports. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%.
Bolt Biotherapeutics Trading Up 1.8%
Shares of Bolt Biotherapeutics stock traded up $0.11 during trading hours on Friday, hitting $6.02. The company’s stock had a trading volume of 7,371 shares, compared to its average volume of 92,357. The stock has a market cap of $11.59 million, a price-to-earnings ratio of -0.36 and a beta of 0.85. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61. Bolt Biotherapeutics has a twelve month low of $3.10 and a twelve month high of $7.78. The firm has a fifty day moving average of $4.58 and a 200-day moving average of $4.52.
Insider Activity
In other Bolt Biotherapeutics news, CEO William P. Quinn sold 9,132 shares of the stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $29,587.68. Following the completion of the transaction, the chief executive officer owned 25,384 shares of the company’s stock, valued at $82,244.16. This trade represents a 26.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, major shareholder Coastlands Capital Lp bought 50,000 shares of the stock in a transaction on Monday, November 9th. The shares were bought at an average cost of $6.38 per share, with a total value of $319,000.00. Following the purchase, the insider owned 462,416 shares of the company’s stock, valued at $2,950,214.08. This trade represents a 12.12% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders sold 38,584 shares of company stock worth $128,361. 9.40% of the stock is owned by insiders.
Analysts Set New Price Targets
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Thursday, October 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $14.50.
Check Out Our Latest Analysis on BOLT
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments that activate the immune system to fight cancer. The company’s approach is designed to combine the targeting capabilities of antibodies with immune-stimulating components that recruit and activate innate immune cells within the tumor microenvironment. Bolt’s proprietary platform centers on Immune-Stimulating Antibody Conjugates, or ISACs. These investigational therapies are intended to bind to specific markers on tumor cells and deliver immune-stimulating payloads, potentially promoting tumor-cell destruction and generating a broader antitumor immune response.
Read More
- Five stocks we like better than Bolt Biotherapeutics
- Firefly Aerospace Lights Up a High-Risk Space Opportunity
- Is Buying the NVIDIA Dip a Mistake? 3 Value Stocks Offer a Different Path Forward
- Costco’s Record $30 Dividend Shows Just How Strong Its Cash Machine Is
- Heavy Lifting: Can USA Rare Earth Turn Its First Sales Into Big Profits?
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
